FK 788
Alternative Names: FK-788Latest Information Update: 19 Jan 2012
At a glance
- Originator Astellas Pharma
- Class Antivirals; Carbamates
- Mechanism of Action Epoprostenol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 31 Mar 2006 Astellas Pharma completes a phase II trial in Hepatitis C in USA (NCT00047814)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 31 Oct 2002 Phase-II clinical trials in Hepatitis C in USA (unspecified route)